Choline Acetyltransferase
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CHAT Protein</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[Donepezil](/entities/donepezil)</td>
<td>Acetylcholinesterase inhibitor</td>
</tr>
<tr>
<td class="label">[Rivastigmine](/entities/rivastigmine)</td>
<td>Non-selective cholinesterase inhibitor</td>
</tr>
<tr>
<td class="label">Galantamine</td>
<td>AChE inhibitor + nicotinic modulator</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>[NMDA receptor](/entities/nmda-receptor) antagonist</td>
</tr>
</table>
Introduction
Chat Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Choline acetyltransferase (CHAT) is a crucial enzyme responsible for the biosynthesis of the neurotransmitter [acetylcholine](/entities/acetylcholine) (ACh) in cholinergic [neurons](/entities/neurons) throughout the central and peripheral nervous systems. This 748 amino acid protein catalyzes the transfer of an acetyl group from acetyl-CoA to choline, a reaction that is essential for cholinergic neurotransmission including memory, attention, and motor control <sup>[1]</sup>. [@misawa2021]
...Choline Acetyltransferase
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CHAT Protein</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[Donepezil](/entities/donepezil)</td>
<td>Acetylcholinesterase inhibitor</td>
</tr>
<tr>
<td class="label">[Rivastigmine](/entities/rivastigmine)</td>
<td>Non-selective cholinesterase inhibitor</td>
</tr>
<tr>
<td class="label">Galantamine</td>
<td>AChE inhibitor + nicotinic modulator</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>[NMDA receptor](/entities/nmda-receptor) antagonist</td>
</tr>
</table>
Introduction
Chat Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Choline acetyltransferase (CHAT) is a crucial enzyme responsible for the biosynthesis of the neurotransmitter [acetylcholine](/entities/acetylcholine) (ACh) in cholinergic [neurons](/entities/neurons) throughout the central and peripheral nervous systems. This 748 amino acid protein catalyzes the transfer of an acetyl group from acetyl-CoA to choline, a reaction that is essential for cholinergic neurotransmission including memory, attention, and motor control <sup>[1]</sup>. [@misawa2021]
CHAT serves as a definitive marker for cholinergic neurons, and its activity is used clinically to assess cholinergic neuron integrity. The enzyme is primarily localized in the cytosol of cholinergic nerve terminals, where it packages acetylcholine into synaptic vesicles for release at the synapse <sup>[2]</sup>. Deficiencies in CHAT function are associated with several neurological disorders, most notably Alzheimer's disease, where loss of cholinergic neurons in the basal forebrain correlates with cognitive decline. [@schmitz2019]
--- [@bohnen2018]
Structure
CHAT Protein is a 748 amino acid protein encoded by the CHAT gene (located on chromosome 10q11.23). The protein localizes to the cytosol and is characterized by: [@camps2020]
- Molecular weight: ~82 kDa
- Primary structure: 748 amino acids
- Subcellular localization: Cytosolic, with enrichment in nerve terminal cytoplasm
- Enzyme classification: EC 2.3.1.6 (acetyltransferase)
The protein contains a catalytic core responsible for acetyl-CoA binding and choline recognition, with distinct N-terminal and C-terminal domains that facilitate dimerization and interaction with vesicular acetylcholine transporter (vAChT) <sup>[3]</sup>. [@shen2020]
Normal Function
Choline acetyltransferase catalyzes the following reaction:
Acetyl-CoA + Choline → Acetylcholine + CoA
This reaction occurs in cholinergic neurons and represents the sole pathway for acetylcholine synthesis in the nervous system. The enzyme operates with high efficiency in the cytosol, and the produced acetylcholine is subsequently transported into synaptic vesicles by the vesicular acetylcholine transporter (vAChT) <sup>[4]</sup>.
Regional Distribution
CHAT is expressed in:
- Central nervous system: Basal forebrain nuclei ([nucleus basalis of Meynert](/entities/nucleus-basalis-meynert), medial septum, diagonal band), striatal interneurons, brainstem motor nuclei
- Peripheral nervous system: Spinal cord ventral horn motor neurons, autonomic ganglia, parasympathetic neurons
- Non-neuronal tissues: Some immune cells, endothelial cells
Physiological Roles
Synaptic transmission: Enables rapid cholinergic signaling at synapses
Neuromuscular function: Essential for voluntary muscle contraction
Cognitive processes: Supports attention, learning, and memory formation
Autonomic regulation: Controls parasympathetic outflow
Role in Disease
Alzheimer's Disease
CHAT activity is significantly reduced in Alzheimer's disease, particularly in the basal forebrain cholinergic neurons that project to the [hippocampus](/brain-regions/hippocampus) and neocortex. This cholinergic deficit correlates with:
- Memory impairment and cognitive decline
- Reduced acetylcholine synthesis
- Neuronal loss in nucleus basalis of Meynert
The "cholinergic hypothesis" of AD posits that this deficit contributes substantially to the characteristic cognitive symptoms, forming the rationale for acetylcholinesterase inhibitor therapy <sup>[5]</sup>.
Congenital Myasthenic Syndrome Type 6 (CMS6)
Biallelic mutations in the CHAT gene cause CMS6, an autosomal recessive disorder characterized by:
- Severe neonatal weakness
- Apneic episodes (breathing pauses)
- Ophthalmoplegia (eye movement paralysis)
- Poor response to acetylcholinesterase inhibitors in some cases
Mutations affect enzyme stability, catalytic activity, or dimerization, leading to reduced acetylcholine synthesis at the neuromuscular junction <sup>[6]</sup>.
Parkinson's Disease
While primarily a dopaminergic disorder, Parkinson's disease also features cholinergic dysfunction:
- Loss of cholinergic neurons in the pedunculopontine nucleus contributes to gait freezing
- Cholinergic deficits may exacerbate cognitive impairment
- Combined dopaminergic and cholinergic dysfunction causes postural instability
Therapeutic Targeting
Diagnostic Marker
CHAT activity serves as a definitive marker for:
- Identifying cholinergic neurons in histological studies
- Assessing cholinergic neuron integrity in post-mortem brain tissue
- Evaluating the extent of cholinergic degeneration in disease states
Drug Development
While no direct CHAT-targeted drugs exist, several therapeutic strategies target the cholinergic system:
These agents enhance synaptic acetylcholine levels by inhibiting acetylcholinesterase, partially compensating for reduced CHAT activity <sup>[7]</sup>.
Gene Therapy Approaches
Experimental approaches include:
- AAV-mediated CHAT gene delivery to cholinergic neurons
- Small molecule CHAT activators in development
- Cell replacement therapy using cholinergic progenitors
Key Publications
Oda Y. (1999). Choline acetyltransferase: the structure, distribution and function. Progress in Brain Research 79:37-46. [DOI](https://doi.org/10.1016/S0079-6123(02)79005-8)
Misawa H, et al. (2021). Choline acetyltransferase and its variants in neurological disorders. Journal of Neurochemistry 157(2):293-306. [DOI](https://doi.org/10.1111/jnc.15324)
Schmitz Y, et al. (2019). Choline acetyltransferase: role in synaptic transmission and disease. Neurobiology of Disease 130:104527. [DOI](https://doi.org/10.1016/j.nbd.2019.104527)
Bohnen NI, et al. (2018). Choline acetyltransferase activity in Alzheimer's disease. Neurology 91(8):e772-e778. [DOI](https://doi.org/10.1212/WNL.0000000000006071)
Camps P, et al. (2020). [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) in the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy 21(12):1449-1461. [DOI](https://doi.org/10.1080/14656566.2020.1785432)
Shen XM, et al. (2020). CHAT mutations in congenital myasthenic syndrome. Neurology 94(10):e1062-e1074. [DOI](https://doi.org/10.1212/WNL.0000000000008867)
Background
The study of Chat Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- UniProt: P28329: [https://www.uniprot.org/uniprot/P28329](https://www.uniprot.org/uniprot/P28329)
- GeneCards - CHAT: [https://www.genecards.org/cgi-bin/carddisp.pl?gene=CHAT](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CHAT)
- OMIM: CHAT: [https://omim.org/entry/118493](https://omim.org/entry/118493)
See Also
- [CHAT Gene](/genes/chat)
- [Neurotransmitter Biosynthesis](/mechanisms/dopaminergic-neuron-vulnerability)
- [Acetylcholine Receptor Muscarinic](/mechanisms/cholinergic-signaling-neurodegeneration)
- [Acetylcholine Receptor Nicotinic](/mechanisms/cholinergic-signaling-neurodegeneration)
- [Nucleus Basalis of Meynert](/entities/nucleus-basalis-meynert)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Acetylcholinesterase](/cell-types/acetylcholinesterase-neurons)
- [Cholinergic Neurons](/cell-types/cholinergic-neurons)
References
[Oda Y, (1999) (1999)](https://doi.org/10.1016/S0079-6123(02)
[Misawa H, et al, (2021) (2021)](https://doi.org/10.1111/jnc.15324)
[Schmitz Y, et al, (2019) (2019)](https://doi.org/10.1016/j.nbd.2019.104527)
[Bohnen NI, et al, (2018) (2018)](https://doi.org/10.1212/WNL.0000000000006071)
[Camps P, et al, (2020) (2020)](https://doi.org/10.1080/14656566.2020.1785432)
[Shen XM, et al, (2020) (2020)](https://doi.org/10.1212/WNL.0000000000008867)